Industry Projects | Projects by Region | Projects by Category | Archived Projects | Project Gallery
 

Exanta - Oral Direct Thrombin Inhibitor for the



VTE encompasses both DVT and PE and is the third most common cardiovascular disease after heart attack and stroke.


Back to Project Details



Related Projects

Ariflo (Cilomilast) - Oral PDE-IV Inhibitor for
Ariflo (cilomilast) is an oral selective phosphodiesterase (PDE) IV...

Fablyn (Lasofoxifene) - Investigational SERM
The product of a joint development programme between Pfizer and...

Rupintrivir -
Agouron Pharmaceuticals, a subsidiary of Pfizer, has pioneered...

Xolair - Biological Therapy
The product of a joint development programme between Tanox, Genentech...

Tarceva - Small Molecule
Tarceva (erlotinib) is an oral anti-cancer drug developed by...

See all projects


Contact us
Advertise with us
Terms and conditions
Privacy
Links
Newsletter sign up
Online magazine sign up

drugdevelopment-technology.com is a product of Net Resources International. Copyright 2011 Net Resources International, a trading division of SPG Media Limited.